Document is current
Any future updates will be listed below
-
Authors
Westcott, Peter M. K. https://orcid.org/0000-0001-9436-4857
Sacks, Nathan J.
Schenkel, Jason M.
Ely, Zackery A.
Smith, Olivia https://orcid.org/0000-0002-2788-9917
Hauck, Haley
Jaeger, Alex M.
Zhang, Daniel
Backlund, Coralie M. https://orcid.org/0000-0002-8012-8340
Beytagh, Mary C. https://orcid.org/0000-0002-1882-1515
Patten, J. J. https://orcid.org/0000-0002-9770-7525
Elbashir, Ryan
Eng, George
Irvine, Darrell J. https://orcid.org/0000-0002-8637-1405
Yilmaz, Omer H. https://orcid.org/0000-0002-7577-4612
Jacks, Tyler https://orcid.org/0000-0001-5785-8911
- License Information
-
More Information
Article History
Received: 1 October 2020
Accepted: 16 July 2021
First Online: 30 September 2021
Competing interests
: T.J. is a member of the Board of Directors of Amgen and Thermo Fisher Scientific and a co-founder of Dragonfly Therapeutics and T2 Biosystems. T.J. serves on the Scientific Advisory Board of Dragonfly Therapeutics, SQZ Biotech and Skyhawk Therapeutics. None of these affiliations represents a conflict of interest with respect to any of the studies described in this manuscript. The Jacks laboratory also currently receives funding from Johnson & Johnson, but this did not support the research described in this manuscript. This work was supported by the Howard Hughes Medical Institute. The remaining authors declare no competing interests.
